Imagin Molecular Corporation Announces Conversion of Positron Convertible Promissory Notes into 70 Million Shares.

OAK BROOK, Ill. -- Imagin Molecular Corporation (OTCBB:IMGM) (the "Company") announced today that the Company's wholly owned subsidiary Positron Acquisition Corp. has reached an agreement with Positron Corporation a publicly owned Texas corporation (OTCBB:POSC) to convert a convertible promissory note into approximately 70,000,000 shares of Positron Corporation's common stock. The transaction will be effective immediately upon ratification of Positron Corporation's increase of its authorized stock. The shares will be restricted and at current prices have a value of approximately $14,000,000.

About Imagin Molecular Corporation:

Imagin Molecular Corporation strategy and focus is dedicated to business opportunities in positron emission tomography (PET) manufacturing. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer's disease. Imagin Molecular Corporation has positioned the Company to be a factor in PET and ancillary molecular imaging businesses. Imagin Nuclear Partners, a wholly owned subsidiary of Imagin Molecular Corporation, is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT scanning equipment. Imagin Molecular Corporation is also the Parent of Cipher Multimedia a new Media Marketing and Distribution Solution Company that provides a Distribution Solution for publishers of digital content. Cipher Multimedia will develop marketing campaigns that will assist Imagin, Positron Corporation and other companies market their products and will continue to provide publishers a distribution solution for digital content.

About Positron Corporation:

Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the University of Texas -- Houston Health Science Center; The Heart Center of Niagara in Niagara Falls, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo. Additional information may be found at http://www.positron.com/.

Forward Looking Statements

Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K.